on SynBiotic SE (isin : DE000A3E5A59)
WEECO Pharma Acquisition Boosts SYNBIOTIC SE's Revenue
SYNBIOTIC SE, a European hemp and cannabis company, has witnessed a significant revenue surge following its acquisition of WEECO Pharma. By the end of October 2024, WEECO's revenue reached EUR 6.75 million, surpassing initial targets. Projections for the full year 2024 now exceed EUR 8 million. In response, sales plans for 2025 and 2026 will be revised upwards.
Daniel Kruse, CEO of SYNBIOTIC, cites WEECO’s integration as a key driver for this growth, highlighting the expanded network of medical cannabis producers. SYNBIOTIC plans additional acquisitions to strengthen its position in cultivation and supply chain sectors.
The positive financial results are drawing increased interest from investors. SYNBIOTIC's Investor Relations embarked on a November roadshow, presenting their strategies to potential investors.
R. E.
Copyright © 2024 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all SynBiotic SE news